GlassScriptPhysician profile
Michele Mcclory
NPI 1851928378
$1,379.64
in general payments reported to CMS, 2019-2025
21 companies · $1,380 in 2025
The $1,380 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,380.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,379.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $163.87 | 2025 | Monjuvi, Jakafi |
| Novartis Pharmaceuticals Corporation | $163.40 | 2025 | |
| Intera Oncology, INC | $150.56 | 2025 | Intera |
| Emd Serono, INC. | $121.86 | 2025 | |
| Merck Sharp & Dohme LLC | $118.24 | 2025 | Keytruda, Keytruda Qlex |
| Genentech USA, INC. | $101.40 | 2025 | Tecentriq, Tecentriq Hybreza, Columvi |
| Janssen Biotech, INC. | $88.06 | 2025 | Tecvayli, Talvey, Darzalex |
| Jazz Pharmaceuticals INC. | $73.04 | 2025 | |
| Exelixis INC. | $62.56 | 2025 | Cabometyx |
| Genzyme Corporation | $53.98 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $33.16 | 2025 | |
| Pharmaessentia USA Corporation | $31.74 | 2025 | Besremi |
| Pfizer INC. | $28.72 | 2025 | |
| Regeneron Healthcare Solutions, INC. | $28.72 | 2025 | Libtayo |
| Lilly USA, LLC | $28.17 | 2025 | Verzenio |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Blueprint Medicines Corporation | $27.38 | 2025 | Ayvakit |
| Beone Medicines USA, INC. | $26.86 | 2025 | Brukinsa |
| Daiichi Sankyo INC. | $25.61 | 2025 | Datroway |
| Adc Therapeutics America, INC. | $22.77 | 2025 | |
| Pharmaand Gmbh | $14.77 | 2025 | Rubraca |
| Tolmar, INC. | $14.77 | 2025 | Rubraca, Eligard |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michele Mcclory listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.